Template:CombiCaVa

From Psychiatrienet
Revision as of 16:43, 22 April 2010 by Ashni (talk | contribs) (Created page with '* Valproate can inhibit carbamazepine metabolic pathways, resulting in raised carbamazepine-epoxide concentrations. <ref> {{Pubmed|9241092|Bernus et al. The mechanism of the carb...')
(diff) ← Older revision | Latest revision (diff) | Newer revision → (diff)
Jump to: navigation, search
  • Valproate can inhibit carbamazepine metabolic pathways, resulting in raised carbamazepine-epoxide concentrations. [1] Valproate can also displace protein-bound carbamazepine and therefore increase the levels of free carbamazepine. This may result in neurotoxicity even when valproate levels are low.[2]
  • Carbamazepine induces metabolism of both itself and valproate via Cytochrome P450 3A3/4 system, which may decrease the serum concentrations of both drugs and increase the risk of relapse.[2]
  • ↑ Bernus et al. The mechanism of the carbamazepine-valproate interaction in humans. Br J Clin Pharmacol 1997;44:21
  • ↑ 2.0 2.1 Cite error: Invalid <ref> tag; no text was provided for refs named freeman
    • Retrieved from "https://wiki.psychiatrienet.nl/w/index.php?title=Template:CombiCaVa&oldid=5536"